|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.380 USD | -1.37% |
|
+3.02% | +20.26% |
| Market Cap | 2.38B 2.1B 1.95B 1.79B 3.36B 231B 3.42B 23.29B 9.09B 113B 8.95B 8.76B 391B | P/E 2026 * |
-3.64x | P/E 2027 * | 15x |
|---|---|---|---|---|---|
| Enterprise Value | 2.46B 2.17B 2.01B 1.85B 3.47B 239B 3.54B 24.08B 9.39B 116B 9.25B 9.05B 404B | EV / Sales 2026 * |
3.68x | EV / Sales 2027 * | 3.03x |
| Free-Float |
94.36% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: BioCryst Pharmaceuticals, Inc.
| 1 day | -1.37% | ||
| 1 week | +3.02% | ||
| Current month | -6.20% | ||
| 1 month | +0.75% | ||
| 3 months | +7.08% | ||
| 6 months | +38.14% | ||
| Current year | +20.26% |
| 1 week | 9.11 |  | 9.69 |
| 1 month | 8.95 | | 11.22 |
| Current year | 6.23 | | 11.22 |
| 1 year | 6 | | 11.22 |
| 3 years | 4.03 | | 11.31 |
| 5 years | 4.03 | | 19.99 |
| 10 years | 1.38 | | 19.99 |
| Manager | Title | Age | Since |
|---|---|---|---|
Charles Gayer
CEO | Chief Executive Officer | 55 | 2025-12-31 |
Babar Ghias
DFI | Director of Finance/CFO | 47 | 2025-07-06 |
Sandeep Menon
CTO | Chief Tech/Sci/R&D Officer | 51 | 2026-04-05 |
| Director | Title | Age | Since |
|---|---|---|---|
Alan Levin
BRD | Director/Board Member | 64 | 2020-02-26 |
Jon Stonehouse
BRD | Director/Board Member | 65 | 2006-12-31 |
| Chairman | 62 | 2025-12-28 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 6/11/26 | Free | Director | 48,834 | 0.0192% | ||
| 6/11/26 | Free | Director | 48,834 | 0.0192% | ||
| 6/11/26 | Free | Director | 48,834 | 0.0192% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -1.37% | +3.02% | +8.94% | +25.57% | 2.38B | |
| +1.23% | +0.35% | +51.62% | +87.98% | 55.92B | |
| +3.71% | +9.92% | +67.33% | +72.60% | 56.67B | |
| +0.25% | +0.55% | -19.67% | -15.22% | 23.28B | |
| +0.72% | -0.05% | +3.84% | +409.54% | 23.28B | |
| -0.36% | +5.73% | +30.99% | -3.58% | 20.54B | |
| -0.42% | +1.23% | +25.92% | -29.77% | 17.78B | |
| -1.44% | +5.67% | +32.54% | +544.11% | 15.9B | |
| -2.54% | -8.73% | +164.11% | +289.45% | 14.64B | |
| +1.22% | -0.05% | +22.58% | +182.63% | 13.99B | |
| Average | +0.10% | +1.44% | +38.82% | +156.33% | 24.44B | |
| Weighted average by Cap. | +0.98% | +3.17% | +43.74% | +135.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | 669M 589M 547M 503M 943M 64.82B 960M 6.54B 2.55B 31.62B 2.51B 2.46B 110B | 726M 639M 593M 546M 1.02B 70.33B 1.04B 7.1B 2.77B 34.3B 2.73B 2.67B 119B |
| Net income | -641M -564M -524M -482M -904M -62.09B -920M -6.26B -2.44B -30.28B -2.41B -2.35B -105B | 141M 124M 115M 106M 198M 13.64B 202M 1.38B 537M 6.65B 529M 517M 23.08B |
| Net Debt | 80.91M 71.16M 66.11M 60.8M 114M 7.84B 116M 791M 308M 3.82B 304M 297M 13.26B | -181M -159M -148M -136M -255M -17.49B -259M -1.76B -688M -8.53B -678M -664M -29.6B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-23 | US$9.380 | -1.37% | 1,635,328 |
| 26-07-22 | US$9.510 | +0.96% | 2,550,092 |
| 26-07-21 | US$9.420 | +3.40% | 2,291,421 |
| 26-07-20 | US$9.110 | -1.94% | 2,383,783 |
| 26-07-17 | US$9.290 | +2.03% | 3,272,762 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- BCRX Stock
Select your edition
All financial news and data tailored to specific country editions
